Vnitr Lek 2009, 55(7-8):631-635

Treatment of hypertension in metabolic syndrome

J. Widimský jr.
Centrum pro hypertenzi III. interní kliniky 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

Hypertension in metabolic syndrome is common. Basic principles of therapeutic approach like decrease of body weight are discussed. Goal blood pressure levels are ≤ 130/80 mm Hg. ACE-inhibitors/AT1-blockers are considered drugs of choice. In most cases it is necessary to combine at least two drugs. Preferred combination is ACE-inhibitor/AT1-blocker + calcium channel blocker.

Keywords: metabolic syndrome; hypertension; treatment

Received: June 23, 2009; Published: July 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský J. Treatment of hypertension in metabolic syndrome. Vnitr Lek. 2009;55(7-8):631-635.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kannel WB. Influence of multiple risk factors on the hazard of hypertension. J Cardiovasc Pharmacol 1990; 16: 353-357. Go to original source...
    2. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607. Go to original source... Go to PubMed...
    3. Reaven GM. Syndrome X 6 years later. J Intern Med 1996; 236: 13-22.
    4. National cholesterol Education Program III (NCEP III) - Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP III). Circulation 2002; 106: 3143-3421. Go to original source...
    5. Kahn R. Metabolic syndrome: is it a syndrome? Does it matter? Circulation 2007; 115: 1806-1810. Go to original source... Go to PubMed...
    6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713. Go to original source... Go to PubMed...
    7. Hansson L, Zanchetti A, Carruthers SG et al. Effect of intensive blood pressure lowering and low dose of aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762. Go to original source... Go to PubMed...
    8. ADVANCE Collaborative Group Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 804-805.
    9. Jamerson K, Weber MA, Bakris GL et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patiens. N Engl J Med 2008; 359: 2417-2428. Go to original source... Go to PubMed...
    10. Redon J. The metabolic syndrome in hypertension. European Society of Hypertension Scientific Newsletter: Update on Hypertension Management 2009; 10: 38.
    11. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology. Guidelines Committee. J Hypertens 2007; 25: 1105-1187.
    12. Widimský J jr., Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Doporučení České společnosti pro hypertenzi. Cor Vasa 2008; 50: K5-K22.
    13. Lindholm LH, Ibsen H, Dahlhof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010. Go to original source... Go to PubMed...
    14. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol 2006; 17 (4 Suppl 2): S90-S97. Go to original source... Go to PubMed...
    15. Yusuf S, Sleight P, Pogue J et al for The Heart Outcomes Prevention Evaluation study investigators. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145-153. Go to original source... Go to PubMed...
    16. Lithell H, Hansson L, Skoog I et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875-886. Go to original source... Go to PubMed...
    17. Staessen JA, Thijs L, Fagard R et al. Effects of immediate versus delayed antihypertensive therapy outcome in the Systolic Hypertension in Europe Trial. J of Hypertension 2004; 22: 847-857. Go to original source... Go to PubMed...
    18. Bakris G, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-2597. Go to original source... Go to PubMed...
    19. Whelton PK, Barzilay J, Cushman WC et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration and normoglycemia: ALLHAT study. Arch Intern Med 2005; 165: 1401-1409. Go to original source... Go to PubMed...
    20. Verdecchia P, Reboldi G, Angeli F et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-969. Go to original source... Go to PubMed...
    21. Almgren T, Wilhelmsen L, Samuelsson O et al. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens 2007; 25: 1311-1317. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.